Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Clinical evidence

Planned confirmatory trial

13 evidence topics · 10 sources

Objective

No evidence found.

Location and study date
Study design
Eligibility criteria

No evidence found.

Treatment
Study outcomes
Rationale for using total functional capacity as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • Planned design only: the trial is described in company releases and the Form 10-Q as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint, and screening is planned to begin in the United States by the end of 2026.
  • Control without a sham procedure: after a Type A meeting in January 2026 the FDA strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; in 2026 it later sought alignment on a confirmatory design that included consideration of a randomized standard-of-care control instead of a sham procedure.
  • Primary endpoint: the UHDRS TFC appears to have a ceiling effect in early stage Huntington's disease, and it lacks core clinimetric data on test-retest reliability and internal consistency.
  • Timing: the FDA stated that the confirmatory study should be well underway, and potentially fully enrolled, at the time of accelerated approval; the company expects the study to be well underway by the time of potential approval.